Nordic Nanovector ASA: Results for the Third Quarter 2020
The Pharma Data
NOVEMBER 18, 2020
Results of preclinical studies demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models published in Journal of Nuclear Medicine. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. Financial Highlights.
40 
Let's personalize your content